Environmental support services group has delivered strong interim results and remains in takeover talks.
In the face of economic uncertainty, environmental support services group Fountains, famed for its vegetation management expertise, delivered strong results for the half to March.
Under CEO Richard Haddon, Fountains has diversified its service range, adding activities such as street cleaning, graffiti removal and waste collection to its grass cutting and tree maintenance core, thereby dramatically expanding its addressable markets. At the same time, the company has focused on larger deals with greater longevity and raised levels of efficiency and innovation.
The benefits of this strategy were revealed at the interim, with operating profits (before bid and board change costs) growing by a third to £800,000, the best half-year operating profit in Fountains’ history.
Pre-tax profits came in at a creditable £388,000 (2008: £650,000), while the interim dividend was increased to 1.25p (2008: 1.1p), underpinned by a significantly improved cash performance.
Turnover growth from £20.7m to £21.2m was modest, however the rail sector, where Fountains previously encountered contract delays, came back strongly and the utility and local authority markets proved profitable hunting grounds.
Encouragingly in February, Fountains clinched its largest-ever contract, a three-year, diverse deal with British Waterways, worth in excess of £5m per annum. And there could be more to come, with Haddon stating ‘we are winning more diverse contracts and our pipeline has much larger contracts with greater longevity within it’.
We think shares in Fountains, which have fallen from a 52-week peak of 135p to present levels, should reclaim further ground given recent strong trading, contract momentum and the improving visibility levels within the business. Furthermore, the company remains in offer talks, which could add some significant extra spice in the months ahead. Buy.
Save 50% off your first year’s subscription to Growth Company Investor magazine, and gain immediate access to all the recommendations online. Click here.
Market cap: £9.847m
PE Forecast: n/a
Share price: 65.5p
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Advertisement
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.